MARKET

SIOX

SIOX

Sio Gene Therapies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.380
0.000
0.00%
After Hours: 2.320 -0.06 -2.52% 16:43 09/24 EDT
OPEN
2.380
PREV CLOSE
2.380
HIGH
2.420
LOW
2.310
VOLUME
604.50K
TURNOVER
--
52 WEEK HIGH
5.74
52 WEEK LOW
1.760
MARKET CAP
173.60M
P/E (TTM)
-3.7977
1D
5D
1M
3M
1Y
5Y
Sio Gene Therapies to Participate in Upcoming Conferences
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor ...
GlobeNewswire · 3d ago
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030
Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region.
AmericaNewsHour · 6d ago
Sickle Cell Disease Drugs Market: Industry Outlook, Classification, Demand, Regional Analysis and Forecast to 2030
Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
AmericaNewsHour · 09/16 06:17
Quite a few insiders invested in Sio Gene Therapies Inc. (NASDAQ:SIOX) last year which is positive news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 09/13 16:16
Sio Gene Therapies Announces Dosing Of First GM1 Gangliosidosis Early Infantile Patient In Ongoing Phase 1/2 Study Of AXO-AAV-GM1 Gene Therapy
Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced dosing of the first Type
Benzinga · 09/09 11:20
Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy
- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts- On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 cohort in October 2021 NEW YORK, and DURHAM, N.C., Sept. 09,...
GlobeNewswire · 09/09 11:00
Sio Gene Therapies Doses First Patient in Low-Dose Cohort of Study of AXO-AAV-GM1 Gene Therapy; Shares Gain Pre-Bell
MT Newswires · 09/09 08:15
SVB Leerink Maintains Outperform on Sio Gene Therapies, Lowers Price Target to $6
SVB Leerink analyst Mani Foroohar maintains Sio Gene Therapies (NASDAQ:SIOX) with a Outperform and lowers the price target from $7 to $6.
Benzinga · 08/12 16:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SIOX. Analyze the recent business situations of Sio Gene Therapies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SIOX stock price target is 7.40 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 20.63M
% Owned: 28.28%
Shares Outstanding: 72.94M
TypeInstitutionsShares
Increased
14
2.13M
New
12
626.69K
Decreased
14
1.12M
Sold Out
14
1.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Frank Torti
Chief Executive Officer/Director
Pavan Cheruvu
Chief Financial Officer/Chief Accounting Officer/General Counsel
David Nassif
Other
Gavin Corcoran
Other
Parag Meswani
Lead Director/Independent Director
Atul Pande
Director
Eric Venker
Director
Kristiina Vuori
Independent Director
Berndt Modig
Independent Director
Senthil Sundaram
No Data
  • All
  • Financials
  • Insiders
More
About SIOX
Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc, Axovant Sciences GmbH, Axovant Sciences Amercia, Inc., Axovant Treasury Holdings, Inc., Axovant Treasury, Inc and Axovant Sciences Europe Ltd. The Company’s clinical-stage programs include AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2 program.

Webull offers kinds of Sio Gene Therapies Inc stock information, including NASDAQ:SIOX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIOX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SIOX stock methods without spending real money on the virtual paper trading platform.